Companies › ADIL

Adial Pharmaceuticals Inc (ADIL)

Institutional ownership, SEC filings and insider activity

Sector: Healthcare & Pharma · SEC CIK 0001513525 · EDGAR filings · Updated 2026-07-16

Adial Pharmaceuticals Inc (ADIL) has reported institutional ownership of 2.5%, with 14 institutional managers holding positions valued at $63.6K per the latest 13F reporting period. SEC filings include an active notice of delisting or failure to satisfy a continued listing rule (8-K Item 3.01), substantial-doubt (going concern) disclosure per the filings.

Latest updates

• 2026-07-16 — Insider transaction reported (Form 4)
• 2026-07-13 — Insider transaction reported (Form 4)
• 2026-07-01 — SCHEDULE 13G/A filed
• 2026-07-01 — Insider transaction reported (Form 4)
• 2026-06-29 — Initial insider ownership filed (Form 3)
• 2026-06-24 — SCHEDULE 13G filed

Institutional ownership overview

According to SEC 13F filings tracked by Sightfile, Adial Pharmaceuticals Inc has 14 institutional holders and institutional ownership of 2.5%.

Insider activity

Insiders reported 0 transactions (0 buys, 0 sells) across 0 reporting insiders, with a net reported value of $0.

Data flags from SEC filings

Related companies

AGAPE ATP CORP (ATPC) · IMMURON LTD (IMRN) · GRI Bio Inc (GRI) · BGM Group Ltd (BGM) · SILEXION THERAPEUTICS CORP (SLXN) · LYRA THERAPEUTICS INC (LYRA)